ClinicalTrials.gg
RecruitingNCT07293338Updated Dec 19, 2025

Prognostic Values of Coronary Microvascular Dysfunction in Patients With Dilated Cardiomyopathy

An observational study in Dilated Cardiomyopathy (DCM), sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
330
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cardiomyopathy, Dilated with a site in China — 13 open to participants now, 14 under way, none of them phase 3. Cardiomyopathy, Dilated · China.

Planned enrollment
10th of 11
330 · median 2,000
Started
2026
with 2 others
Observational
11 of 23
8 open now
Primary completion
2027-11
later than 6 of 13 live
Registered
18th of 23
by date
Lead sponsor
3 of 23
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 23 studies in Cardiomyopathy, Dilated with a site in China, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2026, is one of 11 observational ones, reaches primary completion later than 6 of the 13 other live ones, and was the 18th registered.

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

13 of the 23 studies in Cardiomyopathy, Dilated with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cardiomyopathy, Dilated with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the long-term prognostic of coronary microvascular dysfuction in Patients with Dilated Cardiomyopathy.

The main question it aims to answer is: Does the coronary microvascular dysfunction impact the outcomes in Patients with Dilated Cardiomyopathy.

03

Conditions studied

  • Dilated Cardiomyopathy (DCM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged ≥ 18 years with angiography-confirmed absence of coronary stenosis and a definitive diagnosis of dilated cardiomyopathy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dilated cardiomyopathy comfirmed by echocardiography: LVDd > 55 mm in men or > 50 mm in women.
  • Clinically evident congestive heart failure: Compatible symptoms and signs, and BNP ≥ 35 pg/mL or NT-proBNP ≥ 125 pg/mL, and LV systolic dysfunction defined by \< 45 %.
  • Coronary angiography showing stenosis ≤ 50 % in all major epicardial vessels.

Exclusion criteria

Exclusion Criteria:

  • Patients with coronary artery disease, hypertensive heart disease, rheumatic valvular heart disease, myocarditis, and other secondary cardiomyopathies.
  • poor angiographic image quality
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
330 participants (estimated)
Patient registry
No

Groups and cohorts

  • Coronary microvascular dysfunction

    Procedure: coronary angiography

  • Non-Coronary microvascular dysfunction

    Procedure: coronary angiography

Interventions

  • Procedurecoronary angiography

    Patients should undergo coronary angiography to confirm the absence of significant coronary stenosis. Angio-IMR was calculated based on the angiography.

06

What researchers measure

Primary outcomes

  1. Major adverse cardiac events

    A composite of cardiac death, hospitalization for heart failure, heart transplantation, and device implantation

    Time frame: At 5-year follow-up

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Nov 2027, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 19, 2025
StartEst.
Jan 6, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07293338
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Jan 6, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Dec 19, 2025

Study contacts

Jun Jiang, MD
Contact
21918219@zju.edu.cn
+86 15657125311
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion